Csl Limited · ASX:CSL
Csl — Investor Day (October 2023)
109 slides from Csl's investor day presentation, Oct 16, 2023
Slide 1: CSL Capital Markets Day announcement
For immediate release 16 October 2023 CSL Capital Markets Day For personal use only CSL Limited (ASX:CSL; USOTC:CSLLY) will today hold its Capital Markets Day in Sydney, Australia. Please find attached the presentation materials including a news release outlining the highlights of the day. The brief
Slide 2: CSL Limited Capital Markets Day
For personal use only CSL Limited Capital Markets Day 16 October, 2023
Slide 3: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This presentation contains summary information about CSL Limited (ACN 051 588 348) and its related bodies corporate (together, CSL) and For personal use only CSL's activities as at the date of this presentation. It is information given in summary form only and does no
Slide 4: Agenda
Agenda 9:00 – 9:15 Registration/Coffee Welcome Mark Dehring For personal use only Strategic Overview Paul McKenzie CSL Seqirus Ken Lim CSL Vifor Hervé Gisserot Q&A 10:40 – 11:00 Break CSL Behring Andy Schmeltz Q&A 12:30 – 13:30 Lunch Information & Digital Mark Hill Finance & Sustainability Joy Linto
Slide 5: Strategic Overview
For personal use only Strategic Overview Paul McKenzie CEO & Managing Director
Slide 6: Leading Positions in Large, Growing Markets
Leading Positions in Large, Growing Markets For personal use only Global #1 in plasma protein therapies ~$38 billion industry Global #2 in influenza vaccines ~$7 billion industry Global #1 in iron ~$5 billion industry 5
Slide 7: Positioned for Annual Double-Digit Earnings Growth
Positioned for Annual Double-Digit Earnings Growth For personal use only Leading positions in high Robust R&D Portfolio growth markets • Near-to-mid-term launches • Significant unmet need • Longer-term opportunities across • Durable products driven by platforms and therapeutic areas continued innova
Slide 8: CSL Behring, Seqirus, Vifor
For personal use only CSL | CSL Behring Biotherapies & Rare Disease 7 Driven by Our Promise | CSL Seqirus Vaccines | CSL Vifor lron Deficiency & Nephrology CSL
Slide 9: Strategic Focus Areas
Strategic Focus Areas 5 For personal use only 4 3 Attract, engage, Invest in develop and new digital retain next 2 Deliver our R&D pipeline technologies to drive generation leaders business within our 1 performance Realise COGS investment efficiencies, envelope driving CSL Behring gross Drive top-li
Slide 10: Management Team
Management Team For personal use only Andy Schmeltz Stephen Marlow Hervé Gisserot Bill Mezzanotte Ken Lim EVP, CSL Behring SVP and General SVP and General EVP, Head Research EVP, Chief Strategy Manager CSL Seqirus Manager CSL Vifor & Development Officer United States Australia Switzerland United Sta
Slide 11: CSL Seqirus
For personal use only CSL Seqirus Ken Lim Chief Strategy Officer, CSL
Slide 12: CSL Seqirus growth linked to differentiation strategy
CSL Seqirus growth linked directly to differentiation strategy and core capabilities For personal use only CSL Seqirus historic growth Cornerstones for Success Seasonal Influenza Revenue (US$'M) 1,500 23% CAGR Real World Differentiation Evidence Strategy Platform 1,000 500 - FY16 FY17 FY18 FY19 FY20
Slide 13: CSL Seqirus four strategic pillars
1. CONTINUED 2. BROADEN OUR GROWTH IN PANDEMIC INFLUENZA BUSINESS For personal use only Opportunities in both new CSL Seqirus’s focus and existing markets to Multi-pathogen pandemic capability within its 4 strategic increase our global footprint pillars drives its near 3. GROW BEYOND 4. INVEST IN SC
Slide 14: Influenza still has significant unmet need
Influenza still has significant unmet need, particularly in paediatric and older adult populations For personal use only Seasonal Influenza Burden Hospitalisation Rate Across Ages 70 Hosp. rate Deaths 60 Hospitalisation Rate 12k – 52k 50 (per 10,000) 40 Hospitalisations 30 140-170k 20 10 Infections/
Slide 15: Seqirus will grow the market through differentiation
In influenza, Seqirus will grow the market through differentiation despite lower immunisation rates For personal use only Historic Trend (US) Expectations • Immunisation rates will return over time • Annualisation of COVID-19 boosters will reduce vaccine fatigue COVID-19 • CSL Seqirus growth will ou
Slide 16: Continuous innovation to reduce burden of influenza
CSL Seqirus focused on continuous innovation to reduce the burden of influenza For personal use only Multiple Differentiators Differentiated aH5N1c QIVc Undifferentiated aQIVc aTIV aQIV TIVe sa-mRNA aH5N1 QIVe Development Status: Development Status: • QIVc: 6-month+ age extension • aQIVc: Phase III
Slide 17: sa-mRNA technology differentiates COVID-19 vaccine candidate
sa-mRNA technology differentiates CSL Seqirus COVID-19 vaccine candidate For personal use only Differentiators of sa-mRNA Technology Accelerating to market • Licensing and collaboration agreement Superior response to Omicron strain 1 as a booster in adults vs. approved with Arcturus Therapeutics Inc
Slide 18: New Flu Cell Culture facility in Australia
New Flu Cell Culture facility in Australia to meet growing demand and pandemic protection For personal use only Project is on target for schedule and budget, with first production in Q1 2026 Cell culture manufacturing Anti-venom production Fill/Finish facilities 17
Slide 19: Key Takeaways
Key Takeaways For personal use only • CSL Seqirus is well positioned to continue its success in influenza: ‒ Capacity development well advanced to support aQIVc launch • Continuous innovation will enable CSL Seqirus to outpace market growth: ‒ aQIVc setting new standard of care ‒ sa-mRNA • sa-mRNA t
Slide 20: CSL Vifor
For personal use only CSL Vifor Hervé Gisserot General Manager, CSL Vifor
Slide 21: FY23 solid result with EPS accretive contribution
~14% revenue growth2 FY23 – a solid result with EPS accretive 11 months contribution1 Integration and cost synergies on track For personal use only FY23 Revenue By Therapy Group $m1 Total: $1,989m Iron Therapy Nephrology Dialysis Non-Dialysis 3%, Other, $73 In Market products 7%, Non Dialysis, 3 $13
Slide 22: CSL Vifor strategic framework
CSL Vifor’s strategic framework will set the foundations to drive sustainable, profitable growth For personal use only Maximize Unlock revenue upside in Deliver successful launches Ferinject® / Injectafer® Patient Blood Management and pipeline progress to growth opportunities across CSL strengthen r
Slide 23: Iron market: unique conditions
Iron market: Unique conditions enabling us to drive long-term value For personal use only Market development • Continued market growth due to untapped potential Follow-on • Limited number of follow-on products Competition Innovation • No breakthrough innovation Pricing dynamics • Strong price compet
Slide 24: Iron market: unique conditions
Iron market: Unique conditions enabling us to drive long-term value For personal use only Market Market development • Continued market growth due to untapped potential Experience Follow-on • Limited number of follow on products Competition Innovation • No breakthrough innovation Pricing dynamics • S
Slide 25: Relentless focus on Ferinject / Injectafer growth
Relentless focus on Ferinject® / Injectafer® growth For personal use only GROWTH NEW COMPETITIVE GEOGRAPHIC & MARKET LCM & SCIENTIFIC LANDSCAPE EXPANSION EXCELLENCE • Tendering excellence • New launch markets • Investment in RWE/RWD • Non-clinical differentiation • New indications • New presentation
Slide 26: Patient Blood Management addresses a global health issue
Patient Blood Management addresses a global health issue For personal use only Health Problem Patient Blood Management Benefits Critical need to reduce whole blood Evidence-based approach to preserve For patients: transfusions patient’s own blood • Improved outcomes • Avoidable adverse outcomes Thre
Slide 27: Repeated demonstrations of PBM benefits
Repeated Demonstrations of Patient & Health System Benefits when PBM is fully implemented Benefits for health systems Benefits for patients For personal use only Decrease overall cost of care Improved patient outcomes Length Mortality Infection AMI/stroke of stay Western Australia $18.1 m blood prod
Slide 28: PBM implementation leading to $4-5B addressable market
Countries calling on PBM implementation leading to addressable market of $4-5B across range of specialties For personal use only World Health UK, Germany, 2021 Italy, 2016 Romania, 2018 Organization, 2021 2015: NICE guidelines PBM PBM guidelines PBM guidelines 2022: Preop anaemia Recommendations Pol
Slide 29: CSL uniquely positioned in PBM
CSL is uniquely positioned in PBM to translate evidence- based medicine into evidence-based practice For personal use only Pre-surgery During surgery Post-surgery Benefits Diagnosing & treating Optimizing coagulation Ensuring optimal & fast recovery iron-deficiency (anaemia) of PBM Managing anaemi
Slide 30: Integrated Go to Market operating model
Realising the market opportunity through integrated Go to Market operating model For personal use only RWD/RWE DIRECT ENGAGEMENT Indication expansion & Shape Medical Practice evidence generation through supporting supporting PBM benefits policies Build Influence Scientific & Global & Medical Nationa
Slide 31: Strengthen renal disease position
Strengthen renal disease position along the full spectrum of kidney disease For personal use only Prevent Kidney Chronic kidney Dialysis Damage disease treatment Treatment Preserving renal function Manage complications Manage complications CKD Dialysis 1 Vadadustat (Ex-US) Managing transplant patien
Slide 32: CSL Vifor key value catalysts
CSL Vifor key value catalysts will drive growth into the medium - long term For personal use only Near-term Mid-term Long-term • Ferinject® reimbursement in • Maximize strategic • Nephrology / Transplant China partnerships pipeline • Injectafer® Heart Failure US • PBM revenue upside • BD opportuniti
Slide 33: Thank You / Questions
For personal use only Thank You / Questions
Slide 34: CSL Behring
For personal use only CSL Behring Andy Schmeltz EVP, CSL Behring
Slide 35: CSL Behring: Driving Sustainable, Profitable Growth
CSL Behring: Driving Sustainable, Profitable Growth Working together from Donor to Patient For personal use only PLASMA COLLECTION MANUFACTURING COMMERCIALISATION DONOR. EMPLOYEE. PATIENT. 34
Slide 36: CSL Behring: Driving Sustainable, Profitable Growth
CSL Behring: Driving Sustainable, Profitable Growth Working together from Donor to Patient For personal use only PLASMA COLLECTION MANUFACTURING COMMERCIALISATION Grow Plasma Volume Reduce Plasma Acquisition Cost EMPLOYEE. PATIENT. 35
Slide 37: CSL Behring: Driving Sustainable, Profitable Growth
CSL Behring: Driving Sustainable, Profitable Growth Working together from Donor to Patient For personal use only PLASMA COLLECTION MANUFACTURING COMMERCIALISATION Grow Improve Plasma Ig and Volume Albumin Yield Reduce Plasma Acquisition Cost PATIENT. 36
Slide 38: CSL Behring: Driving Sustainable, Profitable Growth
CSL Behring: Driving Sustainable, Profitable Growth Working together from Donor to Patient For personal use only PLASMA COLLECTION MANUFACTURING COMMERCIALISATION Grow Improve Grow Key Plasma Ig and Medicines and Volume Albumin Deliver Successful Yield Launches Reduce Plasma Acquisition Cost 37
Slide 39: CSL Behring: Driving Sustainable, Profitable Growth
CSL Behring: Driving Sustainable, Profitable Growth Working together from Donor to Patient For personal use only PLASMA COLLECTION MANUFACTURING COMMERCIALISATION Grow Improve Grow Key Plasma Ig and Medicines and Volume Albumin Deliver Successful Yield Launches Reduce Plasma Acquisition Cost 38
Slide 40: Snapshot of CSL Plasma collection network
Snapshot of CSL Plasma’s Industry-Leading Collection Network USA Germany For personal use only Hungary Key figures Note: CSL Plasma also operates five centres in China. • 322 centres U.S. • 15 centres EU 39 • 12 centres opened in last year
Slide 41: Global Plasma Collections Back on Track
Global Plasma Collections Back on Track -22% in FY21 | +24% in FY22 | +31% in FY23 For personal use only Plasma Collections (Litres) FY21 FY22 FY23 FY24 40 Source: Global Donor Management Systems
Slide 42: Leading the Way in Plasma Growth & Efficiency
Leading the Way in Plasma Growth & Efficiency For personal use only Sourcing Sufficient Optimizing Volume Costs 41
Slide 43: Multiple Levers to Support Collections Growth
Multiple Levers to Support Collections Growth, Enabled by Digital Transformation For personal use only • Optimize mix of qualified and new donors • Focus on donor and market segmentation • Leverage personalized messaging and incentives RETENTION FREQUENCY • Deliver best-in-class service • Apply tech
Slide 44: Clear Path to Driving Cost Per Litre Efficiencies
Clear Path to Driving Cost Per Litre (CPL) Efficiencies For personal use only However, we have turned the corner. COVID disruption Further CPL reductions over coming 4 years led to 1 - 3 YEARS Higher donor fees to drive 01 Optimizing Fee collections Structures 2 - 4 Years Lower centre output and Ind
Slide 45: U.S. FDA Nomogram: Important Lever
U.S. FDA Nomogram: Important Lever to Optimize Donations and Drive Plasma Yield For personal use only Collection Target: Weight & Hematocrit Launched in August 2023 Nomogram B Nomogram A Individualized Nomogram Collection Target: Collection Target: Weight Weight, Hematocrit & Height Currently at mos
Slide 46: Benefits of Rika Plasma Donation System
Benefits of Rika Plasma Donation System Currently deployed in ~15 centres Roll-out schedule to be agreed with Terumo by December 2023 For personal use only Donor Donor Sustainable Experience Safety Growth Sustainability Fewer donor Improper Individualized Reduced deferrals; reduced collection volume
Slide 47: Leading the Way in Plasma Growth & Efficiency
Leading the Way in Plasma Growth & Efficiency For personal use only Sourcing Sufficient Optimizing Volume Costs • Digital Transformation • Enhanced Scheduling • Rika Plasma Donation System • Donor Fee Strategy • Nomogram A & I • Fleet Optimization 46
Slide 48: CSL Behring: Driving Sustainable, Profitable Growth
CSL Behring: Driving Sustainable, Profitable Growth Working together from Donor to Patient For personal use only PLASMA COLLECTION MANUFACTURING COMMERCIALISATION Grow Improve Grow Key Plasma Ig and Medicines and Volume Albumin Deliver Successful Yield Launches Reduce Plasma Acquisition Cost 47
Slide 49: Global Manufacturing Presence
Global Manufacturing Presence For personal use only Bern, Broadmeadows, Marburg, Kankakee, Wuhan, Switzerland Australia Germany Illinois, U.S. China • Core products: • Core products: • Core products: • Core products: • Core products: immunoglobulins & immunoglobulins & Human Albumin albumin, albumin
Slide 50: Ig Yield Maximisation Strategy
Ig Yield Maximisation Strategy1 For personal use only Yield Improvements Horizon 1 • Process changes within regulatory filing • Data analytics and plasma allocation • Operational excellence Horizon 2 • Proprietary process improvements with some manufacturing re- tooling • Will require regulatory app
Slide 51: Operational Excellence
Operational Excellence CSL Operating System Delivering Value Across Six Areas For personal use only Productivity Service Reliability Engagement Quality Sustainability Example Value Reduction in cycle Increase level of On Reduction in Increase in Reduction in More efficient time and increased Time In
Slide 52: CapEx Investments Providing Capacity for Growth
CapEx Investments are Providing Capacity for Growth CSL expects CapEx investment needs to reduce as major projects are now coming online For personal use only Annual CapEx Spend New Capacity Online 30% CSL Plasma Centers at Start of FY Reduction in IG Production CapEx Spend COVID Dip 330 303 277 237
Slide 53: CSL Behring: Driving Sustainable, Profitable Growth
CSL Behring: Driving Sustainable, Profitable Growth Working together from Donor to Patient For personal use only PLASMA COLLECTION MANUFACTURING COMMERCIALISATION Grow Improve Grow Key Plasma Ig and Medicines and Volume Albumin Deliver Successful Yield Launches Reduce Plasma Acquisition Cost 52
Slide 54: Strong CSL Behring Portfolio with Growth Drivers
Strong CSL Behring Portfolio with Compelling Growth Drivers For personal use only FY23 Global Revenue Immunoglobins (Ig) $9.3B/+12%1,2 • PRIVIGEN® has >1 Million patient years of therapy • HIZENTRA®, >10 years as worldwide market leader 50% Haemophilia3 13% • IDELVION® is the #1 Factor IX prescribed
Slide 55: Ig Usage Trends by Country
Ig Usage Trends by Country Shows Significant Opportunity, Particularly Beyond US and Australia For personal use only Ig Consumption per Capita (gms/100K) • US, Australia and 327 Canada are the leading 303 countries for per capita Ig utilization 240 • Disease prevalence is consistent globally 153 • C
Slide 56: Behring Ig Growth Opportunities
Behring Ig Growth Opportunities Span Current and New Indications For personal use only 7 Major Markets: Ig Market Volume by Indication (FY23) • Ig demand across core indications IVIG SCIG continues to grow: ‒ Ig replacement in PID, SID ‒ Ig as an immunomodulator in 25% MG, CIDP, ITP 73% 4% 18% • Mul
Slide 57: PRIVIGEN and HIZENTRA: Compelling Offerings
PRIVIGEN® and HIZENTRA® : Compelling Offerings for Patients For personal use only Privigen® Hizentra® • Standard of care IVIg with proven protection • Market leading SCIg offering personalized through reliable Ig restoration treatment options to patients • 15+ years in PID and ITP; • Recommended for
Slide 58: Behring Ig Portfolio to Outpace Market Growth
Behring Ig Portfolio to Outpace Market Growth For personal use only Projected Global Ig Market Volume* IVIg Volume Ig Market 30+% share 5-Yr Vol 6-8% high single-digits CAGR FY23 FY28 SCIg • Improving Ig market supply, strong underlying demand and improved diagnosis rates in PID Volume • PRIVIGEN® (
Slide 59: Haemophilia B Disease Overview and Unmet Needs
Haemophilia B Disease Overview and Unmet Needs For personal use only Haemophilia B: A rare genetic bleeding disorder It results from the ~38K people2 ~20K people absence or deficiency of Diagnosed with Treated with Factor coagulation Factor IX Haemophilia B IX therapies (FIX)1 worldwide in 2021[2] S
Slide 60: IDELVION and HEMGENIX: Leading Through Innovation
IDELVION® and HEMGENIX®: Leading Through Innovation For personal use only Idelvion Hemgenix® • Well established standard of care • Provides greater bleed protection vs prophy • Provides highest factor levels for the longest ‒ 63% patients reported zero bleeds in the 7 to period of time of any FIX re
Slide 61: Behring Haemophilia B Portfolio to Outpace Market
Behring Haemophilia B Portfolio to Outpace Market Growth For personal use only Projected Global Haemophilia B Market Revenue* Haem B Market 5-Yr Rev 4-6% high single-digits CAGR Revenue • Haemophilia B market expected to grow due the launch of advanced therapies 35-40% including gene therapy (GT) sh
Slide 62: Hereditary Angioedema Disease Overview
Hereditary Angioedema (HAE) Disease Overview and Unmet Needs For personal use only Hereditary Angioedema: A rare genetic disorder • HAE results from missing or low levels of a protein called C1 esterase inhibitor (C1-INH) and can cause 32% 51% attacks of swelling, and 1/40,000-50,000 50% Chance of p
Slide 63: HAEGARDA and Garadacimab Prophylactic Efficacy
HAEGARDA® and Garadacimab Best in Class Prophylactic Efficacy For personal use only Haegarda® Garadacimab • Addresses the root cause of HAE by replacing • First Factor XIIa therapy for HAE prevention missing or dysfunctional C1-INH working at the top of the cascade • Reduces the median frequency of
Slide 64: Behring HAE Portfolio to Outpace Market Growth
Behring HAE Portfolio to Outpace Market Growth For personal use only Projected Global HAE Market Revenue HAE Market garadacimab 5-Yr Rev 4-6% high single-digits CAGR Revenue • Improved diagnosis rates and new prophylaxis therapies will drive market growth 30+% • CSL portfolio addresses the needs of
Slide 65: Portfolio Enabled by Additional In-line Growth Drivers
Portfolio Enabled by Additional In-line Growth Drivers FY23 Global Revenue For personal use only $9.3B/+12%1,2 Hereditary Angioedema (HAE) Haemophilia3 • CSL sustained market leadership 7% • Leverage data generation and real-world (11% in FY23) experience in expanded indications 13% OTHER • Growth i
Slide 66: CSL Behring: Driving Sustainable, Profitable Growth
CSL Behring: Driving Sustainable, Profitable Growth Working together from Donor to Patient For personal use only PLASMA COLLECTION MANUFACTURING COMMERCIALISATION Grow Improve Grow Key Plasma Ig and Medicines and Volume Albumin Deliver Successful Yield Launches Reduce Plasma Acquisition Cost 65
Slide 67: CSL Behring: Driving Sustainable, Profitable Growth
CSL Behring: Driving Sustainable, Profitable Growth Working together from Donor to Patient For personal use only PLASMA COLLECTION MANUFACTURING COMMERCIALISATION 1 Improve Ig and Grow Key Medicines and Albumin Deliver Successful Deploy Rika, Yield Launches Nomogram A/I, digital transformation and o
Slide 68: CSL Behring: Driving Sustainable, Profitable Growth
CSL Behring: Driving Sustainable, Profitable Growth Working together from Donor to Patient For personal use only PLASMA COLLECTION MANUFACTURING COMMERCIALISATION 1 2 Grow Key Medicines and Deliver Successful Deploy Rika, Deliver Horizon 1 yield Launches Nomogram A/I, improvements; advance digital t
Slide 69: CSL Behring: Driving Sustainable, Profitable Growth
CSL Behring: Driving Sustainable, Profitable Growth Working together from Donor to Patient For personal use only PLASMA COLLECTION MANUFACTURING COMMERCIALISATION 1 2 3 Deploy Rika, Deliver Horizon 1 yield Outpace market Nomogram A/I, improvements; advance growth in Ig, digital transformation Horizo
Slide 70: Thank You / Questions
For personal use only Thank You / Questions 69
Slide 71: Information and Digital
For personal use only Information and Digital Mark Hill CDIO
Slide 72: Selective in choosing digital opportunities
We are Our focus areas include: selective in For personal use only choosing 1 • Interactions with donors • The acceleration of science in pursuit of new therapies digital • Scaling the enterprise opportunities with the greatest 2 Under these focus areas lies a massive injection of information and au
Slide 73: Value drivers for information and digital
Value drivers for information and digital For personal use only Differentiation Integration Automation Information Cybersecurity Making donations Unified and Self-healing Making data the Maintaining easier, while standard business processes that connective tissue acceptable levels of risk ensuring u
Slide 74: Fusion of business and technology: Plasma
Fusion of business and technology Plasma: Making donations easier, creating a more PLASMA positive donor experience, and bring in more R&D Enterprise donors For personal use only Digital Experience Data Artificial Intelligence Innovation 73
Slide 75: Fusion of business and technology: R&D
Fusion of business and technology R&D: Merging biological and computer science Plasma R&D for pipeline growth Enterprise For personal use only Scientific Insights Accelerating the pace of discovery. Operational Excellence Integrating our R&D systems and processes across businesses. Data The connecti
Slide 76: Fusion of business and technology: Enterprise
Fusion of business and technology Enterprise: Capabilities for business Plasma R&D performance and operational leverage ENTERPRISE For personal use only CSL Enterprise Information Real-time data flows that CSL drive insights and seamless ecosystem connections. Automation Self-healing processes that
Slide 77: Generative AI framework
Our Generative AI framework focuses on broad productivity, business outcomes Illustrative use cases and long-term value innovation 3 Accelerate time to trial For personal use only Focus Area 3: Breakthrough Innovation 3 Improve pharmacovigilance reporting Create game-changing outcomes and differenti
Slide 78: Cybersecurity remains the biggest risk
Cybersecurity remains the biggest risk in digital transformation For personal use only Generative AI risks: Shifting regulatory requirements and geopolitical threats • Data leakage • Hallucination (generating inaccurate responses) Generative AI • Making cyber criminals more efficient and effective •
Slide 79: Takeaways
Takeaways For personal use only We see digitalization as a mechanism of scale, accelerating our business growth at less physical cost. Fusion of business and technology are potential differentiators of our business in the donor experience, the speed of science, and enterprise leverage (extending our
Slide 80: Finance and Sustainability
For personal use only Finance and Sustainability Joy Linton CFO
Slide 81: Disciplined Management of Capital
Disciplined Management of Capital For personal use only Growing Cash Earnings Maintain strong balance Returns to shareholders Re-invest in the Business Capital structure sheet • Dividend growth in line • R&D investment of 10 -11% • Annual Review • Net debt / EBITDA target with NPATA growth of revenu
Slide 82: Capital Expenditure
Capital Expenditure1 For personal use only Key Points Capex US$m % of Revenue • Significant investment continued 1,400 14% during COVID years providing ~30% 13% capacity to meet future demand 1,200 12% • Mid term capex needs reduced 1,000 11% following natural run off of 10% intensive program 800 9%
Slide 83: Key Capital Projects - Completion Timeline
Key Capital Projects - Completion Timeline FY24 FY25 FY26 FY27 FY28 FY29 FY30 2023 2024 2025 2026 2027 2028 2029 2030 For personal use only Rika Device Rollout Technology Veeva (Quality, PhV) Broadmeadows: Mod 3 – Frac + CSL112 Base Frac Future Base Frac – delayed need with Yield initiatives Ig Yiel
Slide 84: ROIC Outlook
ROIC Outlook For personal use only Earnings expansion fuelled by: • Differentiated product portfolios Steady improvement1 in • Drive IG growth ROIC fuelled by double • New product launches digit earnings growth • CSL Behring gross margin recovery • Continued growth in CSL Seqirus • CSL Vifor strateg
Slide 85: Continued active management of inventory
Continued active management of inventory Increase in plasma volumes and CPL have accentuated the value of inventory For personal use only 8,000 CPL 200.0 7,500 Key Challenges 180.0 7,000 6,500 160.0 • Balancing inventory build versus 6,000 140.0 fulfilling patient demand 5,500 Plasma Volumes 5,000 1
Slide 86: Strong Balance Sheet
Strong Balance Sheet Debt is strongly weighted towards long tenors at fixed rates Strong liquidity and competitive access to debt • Net Debt / EBITDA 2.5x, expected to be ~2.0x by end FY24 capital across multiple markets For personal use only • Business focus for further debt reduction to ensure cre
Slide 87: Sustainability
For personal use only Sustainability
Slide 88: Sustainability Pillars
Sustainability Pillars Ongoing targeted For personal use only Diagnostic Ambitions Benefits efforts / Baseline / Targets Roadmap Execution realization ENVIRONMENT • Reduce Carbon Emissions (E) • Reduce Waste & Emissions in delivering on our the supply chain In • Environmental considerations In progr
Slide 89: Key Sustainability Indicators and Highlights
Key Sustainability Indicators and Highlights Environment Social Workforce For personal use only 100% SBTi 1.5⁰C 94% 475 59% of plasma donors are regulatory inspections of Female Employees Renewable Electricity (RE) Committed to be aligned willing to donate again and our manufacturing across all our
Slide 90: Research & Development
For personal use only Research & Development Bill Mezzanotte Executive Vice President, Head of R&D
Slide 91: ONE CSL R&D
For personal use only 90 ONE CSL R&D
Slide 92: Focus Through Our Therapeutic Areas and Platforms
Focus Through Our Therapeutic Areas and Platforms For personal use only New: Nephrology 91
Slide 93: Enhancing R&D's Global Capabilities
Enhancing R&D’s Global Capabilities For personal use only Melbourne, Australia Marburg, Germany Waltham, USA • New Global Headquarters and • New R&D Campus • R&D centre supporting sa-mRNA Centre for R&D in Melbourne • ~40,000 m2 for >500 R&D technology for seasonal & Biomedical Precinct employees in
Slide 94: CSL R&D Portfolio – FY23
CSL R&D Portfolio – FY23 Phase I Phase II Phase III Registration/Post-Registration Anumigilimab (CSL324) HIZENTRA® HIZENTRA® INJECTAFER® HAEGARDA® FLUAD® Quadrivalent Anti-G-CSFR mAb (HS) (SSc) (DM) (Ferric carboxymaltose) (HAE) Adjuvanted Egg-based For personal use only (HF-ID) Influenza Vaccine CS
Slide 95: CSL R&D Portfolio – FY23 Transitions
CSL R&D Portfolio – FY23 Transitions Phase I Phase II Phase III Registration/Post-Registration Anumigilimab (CSL324) CSL301 HIZENTRA® INJECTAFER® HAEGARDA® /BERINERT FLUAD® Quadrivalent Anti-G-CSFR mAb (HS) α2AP mAb (PE) (DM) (Ferric carboxymaltose) (HAE) Adjuvanted Egg-based For personal use only (
Slide 96: CSL R&D Portfolio – FY24
CSL R&D Portfolio – FY24 Phase I Phase II Phase III Registration/Post-Registration CSL889 Anumigilimab (CSL324) HIZENTRA® HAEGARDA® FILSPARI (Sparsentan) AUDENZ™ For personal use only Hemopexin (SCD) Anti-G-CSFR mAb (HS) (DM) (HAE) Dual ETA & AT1 antagonist Adjuvanted Cell-based (IgAN) Monovalent
Slide 97: R&D Focus: Investments Coming to Fruition
R&D Focus Investments Coming to Fruition For personal use only Deliver a Promising Portfolio Strengthen our Core Platforms • CSL112 • Flu Cell Culture yield • Garadacimab HAE • Iron evidence & • Clazakizumab ca-AbMR optimisation • KCENTRA® Trauma • CSL964 aGvHD • Patient Blood Management • Sparsenta
Slide 98: Ig Yield Horizon
Ig Yield Horizon 2 Manufacturing For personal use only Enhancement Product Comparability Performance Assessment Iterative Health Authority Engagement LABORATORY SCALE PILOT SCALE STABILITY FILING 97
Slide 99: Significant Target Launch Dates
Significant Target Launch Dates For personal use only FY23 FY24 - FY27 HEMGENIX ® HIZENTRA® VELPHORO® CSL964 AAT Etranacogene SCIg 20% Liquid (DM) Sucroferric oxyhydroxide (aGvHD Treatment) dezaparvovec (Haem B) (Serum P control in CKD) China BERINERT® SC HIZENTRA® KORSUVA ® /KAPRUVIA® CSL964 AAT C1
Slide 100: Forward-Looking Portfolio Highlights – FY24
Forward-Looking Portfolio Highlights – FY24 Cardiovascular Haematology Respiratory & Metabolic For personal use only • CSL112 (ApoA-1) AMI Phase III top line results • IDELVION ® China Phase III first patient in • Trabikibart (Anti-Beta Common) ASTH Phase I • Clazakizumab (ESKD) • Vamifeport (SCD) l
Slide 101: Thank You / Questions
For personal use only Thank You / Questions 100
Slide 102: Concluding Remarks
For personal use only Concluding Remarks Paul McKenzie CEO & Managing Director
Slide 103: Financial Outlook
Financial Outlook For personal use only FY24 Guidance Revenue Growth of 9-11% @CC RE-AFFIRMED NPATA Growth of 13-17% @CC $2.9 - $3.0 billion @CC RE-AFFIRMED Capex Down 30% Operating efficiency G&A ~5% of revenue Balance sheet Circa 2x net debt / EBITDA Outlook CSL Behring gross margin Recovering to
Slide 104: Strategic Positioning
Strategic Positioning • Growing global markets with significant unmet patient need For personal use only • Best in class, durable products driven by continued innovation • Scaled manufacturing platforms underpinned by embedded know how Near Term / Recent Activity Market Opportunities Outpacing indus
Slide 105: R&D Programs – Near Term Milestones
R&D Programs – Near Term Milestones Opportunity FY24 For personal use only Garadacimab (HAE) Potentially best in class treatment option for EU, US & JP submissions HAE patients Clazakizumab (ca-AbMR) AbMR is leading cause of transplant failure Phase III study - 200 pts enrolled KCENTRA® (Trauma) Tra
Slide 106: Positioned for Annual Double-Digit Earnings Growth
Positioned for Annual Double-Digit Earnings Growth For personal use only Leading positions in high Robust R&D Portfolio growth markets • Near-to-mid-term launches • Significant unmet need • Longer-term opportunities across • Durable products driven by platforms and therapeutic areas continued innova
Slide 107: CSL Contacts
For personal use only CSL Contacts Mark Dehring VP Investor Relations +61 3 9389 3407 mark.dehring@csl.com.au Bernard Ronchi Investor Relations +61 3 9389 3470 bernard.ronchi@csl.com.au Stephen McKeon Investor Relations +61 3 9389 6798 stephen.mckeon@csl.com.au
Slide 108: News Release: CSL well-positioned to deliver sustainable, profitable growth
NEWS RELEASE For immediate release 16 October 2023 CSL well-positioned to deliver sustainable, profitable growth SYDNEY, Australia – 16 October 2023 – CSL Limited will today hold its inaugural Capital Markets Day to brief investors on its strategies to deliver annual double-digit earnings growth und
Slide 109: For further information, please contact
For further information, please contact: Jimmy Baker Communications CSL Limited P: +61 450 909 211 E: jimmy.baker@csl.com.au For personal use only 1 ROIC is expected to modestly soften in FY24, driven by the timing mismatch between the raising of funds to acquire Vifor Pharma and the payment of cons